Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Sep 28, 2015
Clinical News

Tofacitinib: Phase III data

BioCentury | Jul 13, 2015
Clinical News

Xeljanz tofacitinib regulatory update

BioCentury | Apr 13, 2015
Clinical News

Xeljanz tofacitinib: Additional Phase III data

BioCentury | Feb 16, 2015
Clinical News

Xeljanz tofacitinib regulatory update

BioCentury | Apr 28, 2014
Clinical News

Xeljanz tofacitinib: Phase III data

BioCentury | Apr 14, 2014
Clinical News

Xeljanz tofacitinib: Additional Phase III data

BioCentury | Mar 3, 2014
Clinical News

Xeljanz tofacitinib regulatory update

BioCentury | Nov 25, 2013
Clinical News

Xeljanz tofacitinib regulatory update

BioCentury | Oct 14, 2013
Clinical News

Xeljanz tofacitinib: Phase III data

BioCentury | Oct 14, 2013
Clinical News

Xeljanz tofacitinib: Phase III data

Items per page:
1 - 10 of 50